Studies on integrins in breast cancer and pancreatic ductal adenocarcinoma have demonstrated that integrin signaling can increase the secretion of EGF, which may bypass the blocking effect of mAbs, such as cetuximab. This evidence concerns the gene EGF and breast cancer.